Physician profile
Peter Simek
NPI 1568443448
$857.08
in general payments reported to CMS, 2019-2025
12 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.34 · 2020: $99.38 · 2021: $74.36 · 2022: $51.11 · 2023: $25.48 · 2024: $250 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591 · Education: $23.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.93 |
| Education | $23.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $419.52 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $152.26 | 2020-2025 | |
| Abbvie INC. | $51.51 | 2021 | |
| Exact Sciences Corporation | $37.43 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $37.41 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.63 | 2020-2021 | |
| Amgen INC. | $31.08 | 2025 | Repatha |
| Astellas Pharma US INC | $24.62 | 2024 | Veozah |
| Novo Nordisk INC | $18.70 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.34 | 2019 | |
| Lucid Diagnostics INC. | $17.12 | 2022 | |
| Lilly USA, LLC | $15.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Simek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.